UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study

BJU international, 2022-12, Vol.130 (6), p.799-808

2022

Volltextzugriff (PDF)

Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer

Acta oncologica, 2024-06, Vol.63 (1), p.503-510

2024

Volltextzugriff (PDF)

Deep learning‐based classification and structure name standardization for organ at risk and target delineations in prostate cancer radiotherapy

Journal of applied clinical medical physics, 2021-12, Vol.22 (12), p.51-63

2021

Volltextzugriff (PDF)

Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens

The Prostate, 2020-02, Vol.80 (2), p.214-224

2020

Volltextzugriff (PDF)

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET

Nuclear medicine communications, 2023-11, Vol.44 (11), p.997-1004

2023

Volltextzugriff (PDF)

Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C

Molecular oncology, 2022-02, Vol.16 (4), p.846-859

2022

Volltextzugriff (PDF)

Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients

The Prostate, 2018-01, Vol.78 (1), p.48-53

2018

Volltextzugriff (PDF)

Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer

The Prostate, 2006-10, Vol.66 (14), p.1512-1520

2006

Volltextzugriff (PDF)

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden

Acta oncologica, 2018-02, Vol.57 (2), p.187-194

2018

Volltextzugriff (PDF)

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

The Lancet (British edition), 2019-08, Vol.394 (10196), p.385-395

2019

Volltextzugriff (PDF)

Dietary intake of phytoestrogens, estrogen receptor‐beta polymorphisms and the risk of prostate cancer

The Prostate, 2006-10, Vol.66 (14), p.1512-1520

2006

Volltextzugriff (PDF)

Different fractionation schedules of radiotherapy to the primary tumor in metastatic hormone sensitive prostate cancer (Hypo-M1)

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (6_suppl), p.TPS192-TPS192

2022

Volltextzugriff (PDF)

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Annals of oncology, 2017-10, Vol.28 (10), p.2464-2471

2017

Volltextzugriff (PDF)

Breast Cancer as a Second Primary in Patients With Prostate Cancer—Estrogen Treatment or Association With Family History of Cancer?

The Journal of urology, 2006-08, Vol.176 (2), p.538-543

2006

Volltextzugriff (PDF)

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial

JOURNAL OF CLINICAL ONCOLOGY, 2018, Vol.36 (15_suppl), p.5000-5000

2018

Volltextzugriff (PDF)

Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial

ANNALS OF ONCOLOGY, 2017, Vol.28 (Suppl. 5), p.v281-v281

2017

Volltextzugriff (PDF)

MP27-01 TIME ON TREATMENT WITH ABIRATERONE IN MEN WITH DE NOVO METASTATIC CASTRATION SENSITIVE PROSTATE CANCER

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer

Acta oncologica, 2023, Vol.62 (12), p.1698-1706

2023

Volltextzugriff (PDF)

Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study

Acta oncologica, 2022, Vol.61 (3), p.328-332

2022

Volltextzugriff (PDF)

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC)

JOURNAL OF CLINICAL ONCOLOGY, 2015, Vol.33 (7_suppl), p.236-236

2015

Volltextzugriff (PDF)

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC)

JOURNAL OF CLINICAL ONCOLOGY, 2015, Vol.33 (15_suppl), p.e16065-e16065

2015

Volltextzugriff (PDF)

Robust treatment planning of dose painting for prostate cancer based on ADC-to-Gleason score mappings - what is the potential to increase the tumor control probability?

Acta oncologica, 2021-02, Vol.60 (2), p.199-206

2021

Volltextzugriff (PDF)

PET/MRI attenuation correction in the pelvic region with a statistical decomposition method

European journal of nuclear medicine and molecular imaging, 2019, Vol.46 (SUPPL 1), p.S289

2019

Volltextzugriff (PDF)

Association between the Presence of Bacterial 16S RNA in Prostate Specimens Taken during Transurethral Resection of Prostate and Subsequent Risk of Prostate Cancer (Sweden)

Cancer causes & control, 2006-11, Vol.17 (9), p.1127-1133

2006

Volltextzugriff (PDF)

Toxicity in patients receiving adjuvant docetaxel plus hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

Prostate cancer and prostatic diseases, 2012, Vol.15 (3), p.303

2012

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(40)
Tagungsberichte
(2)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study

Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer

Deep learning‐based classification and structure name standardization for organ at risk and target delineations in prostate cancer radiotherapy

Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET

Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C

Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients

Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Dietary intake of phytoestrogens, estrogen receptor‐beta polymorphisms and the risk of prostate cancer

Different fractionation schedules of radiotherapy to the primary tumor in metastatic hormone sensitive prostate cancer (Hypo-M1)

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Breast Cancer as a Second Primary in Patients With Prostate Cancer—Estrogen Treatment or Association With Family History of Cancer?

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial

Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial

MP27-01 TIME ON TREATMENT WITH ABIRATERONE IN MEN WITH DE NOVO METASTATIC CASTRATION SENSITIVE PROSTATE CANCER

Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer

Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC)

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC)

Robust treatment planning of dose painting for prostate cancer based on ADC-to-Gleason score mappings - what is the potential to increase the tumor control probability?

PET/MRI attenuation correction in the pelvic region with a statistical decomposition method

Association between the Presence of Bacterial 16S RNA in Prostate Specimens Taken during Transurethral Resection of Prostate and Subsequent Risk of Prostate Cancer (Sweden)

Toxicity in patients receiving adjuvant docetaxel plus hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

Aktive Filter

Suchergebnisse filtern